Today's Date:
Become a fan on Facebook Follow us on Twitter Connect with us on LinkedIn Bookmark and Share Follow us on Youtube
Site Navigation:

National Cancer Institute

Laboratory Information:

National Cancer Institute
Bethesda, MD 20892
Technology Transfer Website:
Agency/Department: Dept. of Health and Human Services
Region: Mid-Atlantic

FLC Laboratory Representative:

Ms. Karen Maurey
Phone: (240) 276-5530
Fax: (240) 276-5504

Background/History of the Laboratory:

The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS). The NCI, established under the National Cancer Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.

The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Accomplishments in Technology Transfer:

AIDS test kits, Fludara®, Gardasil®, HIVID®, Kepivance®, Multi-replica blotting kit for proteins, NeuTrexin®, PathVysion® HER-2 DNA probe kit, PhenoSenseTM HIV phenotype tests, PixCell® Laser Capture Microdissection system (LCM), Prezista®, soluble IL-2 receptor assays, Squirrel-Free capsaicin-treated birdseed, Taxol®, Velcade®, Videx®, Vitravene® and Zevalin®. More information on NCI success stories can be found at

Mission of the Laboratory:

The National Cancer Institute supports and coordinate research projects conducted by universities, hospitals, research foundations, and businesses throughout this country and abroad through research grants and cooperative agreements; conducts research in its own laboratories and clinics; supports education and training in fundamental sciences and clinical disciplines for participation in basic and clinical research programs and treatment programs relating to cancer through career awards, training grants, and fellowships; supports research projects in cancer control; supports a national network of cancer centers; collaborates with voluntary organizations and other national and foreign institutions engaged in cancer research and training activities; encourages and coordinates cancer research by industrial concerns where such concerns evidence a particular capability for programmatic research; collects and disseminates information on cancer; supports construction of laboratories, clinics, and related facilities necessary for cancer research through the award of construction grants.


Technology Transfer Mechanisms:

  • Clinical Trial Agreements (CTAs)
  • Confidential Disclosure Agreements (CDAs)
  • Employee Invention Report (EIR)
  • Fellowships
  • Material Transfers
  • Materials-Cooperative Research and Development Agreement (Materials CRADA)
  • Natural Products Branch-Developmental Therapeutics Program Memorandum of Understanding (MOU)
  • Cooperative Research and Development Agreements (CRADAs)
  • Small Business Innovative Research (SBIR)

Technology Areas of Expertise:

  • AIDS Cancers
  • Analytic Epidemiology
  • Applied Cancer Screening
  • Basic and Biobehavioral Research
  • Basic Prevention Science
  • Behavioral Research
  • Biochemistry and Pharmacology
  • Biological Modifiers
  • Biometry
  • Cancer and Nutrition
  • Cancer Biology
  • Cancer Biomarkers
  • Cancer Cell Biology
  • Cancer Complementary and Alternative Medicine
  • Cancer Control and Population Sciences
  • Cancer Etiology
  • Cancer Genomics
  • Cancer Immunology and Hematology
  • Cancer Nanotechnology
  • Cancer Prevention
  • Cancer Statistics
  • Cancer Surveillance
  • Cancer Survivorship
  • Cancer Treatment and Diagnosis
  • Chemopreventive Agent Development
  • Clinical and Genetic Epidemiology
  • Clinical Oncology
  • Clinical Proteomics Technology
  • Clinical Trials
  • Community Oncology Prevention Trials
  • Diagnostic Imaging
  • Diagnostics Research
  • DNA and Chromosome Aberrations
  • Drug Discovery
  • Early Detection
  • Epidemiology and Genetics
  • Gastrointestinal and Other Cancers
  • Health Communication and Informatics
  • Health Promotion
  • Health Services and Economics
  • Imaging Technology Development
  • Integrated Tumor Biology
  • Integrated Tumor Biology
  • Lung and Upper Aerodigestive Cancer
  • Molecular Imaging
  • Mouse Models of Human Cancers
  • Nutritional Science
  • Outcomes Research
  • Prostate and Urologic Cancer
  • Radiotherapy Development
  • Resources Development
  • Risk Factor Monitoring and Methods
  • Statistical Research and Applictions
  • Surgical Oncology
  • Surveillance Research
  • Technology Development/Cancer Diagnosis Program
  • Tobacco Control and Research
  • Tumor Biology and Metastasis